γ-Cyhalothrin 是一种具有口服活性且可穿透血脑屏障的 II 型合成拟除虫菊酯类杀虫剂 (Insecticide),是 λ-Cyhalothrin (MS-Y46776) 的杀虫活性对映体,可破坏电压门控钠通道,诱导大鼠流涎并出现自发活动减少,对水生无脊椎动物和鱼类产生毒性作用,引发水生群落水平的效应,并可抑制住宅草坪交错带中寻求宿主的肩突硬蜱 (Ixodes scapularis) 若虫,可用于杀虫的相关研究。
产品编号: MS-A40168 CAS No.: 76703-62-3 分子式: C23H19ClF3NO3 分子量: 449.85
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

γ-Cyhalothrin 是一种具有口服活性且可穿透血脑屏障的 II 型合成拟除虫菊酯类杀虫剂 (Insecticide),是 λ-Cyhalothrin (MS-Y46776) 的杀虫活性对映体,可破坏电压门控钠通道,诱导大鼠流涎并出现自发活动减少,对水生无脊椎动物和鱼类产生毒性作用,引发水生群落水平的效应,并可抑制住宅草坪交错带中寻求宿主的肩突硬蜱 (Ixodes scapularis) 若虫,可用于杀虫的相关研究。

生物实验数据

生物活性 γ-Cyhalothrin is an orally active, blood-brain barrier-penetrating type II synthetic pyrethroid insecticide that is the insecticidal active enantiomer of λ-Cyhalothrin (MS-Y46776), disrupts voltage-gated sodium channels, induces salivation and decreased spontaneous activity in rats, exerts toxic effects on aquatic invertebrates and fish, triggers effects at the aquatic community level, and inhibits host-seeking Ixodes scapularis nymphs in residential lawn ecotones, and can be used for insecticidal research.
体外研究
(In Vitro)

Gamma-cyhalothrin 对无脊椎动物表现出 HC5 为 0.47 ng/L 的中值,对鱼类的 HC5 中值为 23.7 ng/L,群落水平的无观察效应浓度 (NOEC群落) 为 5 ng/L。

体内研究
(In Vivo)

γ-Cyhalothrin (0.05% 制剂,362 g/92.9 m2;单次) 在处理后长达 4 周内,可使住宅草坪交错带样地中寻求宿主的肩突硬蜱 (Ixodes scapularis) 若虫数量减少 89-97.6%。
γ-Cyhalothrin (0.0938-4 mg/kg;口服;单次) 可使雄性 Long-Evans 大鼠的自发活动呈剂量依赖性降低,诱导流涎。

Animal Model: nymphal stage
Dosage: 0.05% γ-Cyhalothrin, 362 g/92.9 m2 (equivalent to 292.5 mg active ingredient per 150 m2 plot)
Administration: topical application; single dose
Result: Reduced nymphal Ixodes scapularis density by 97.7% in Eau Claire County and 97.4% in Sauk County at 1 week postapplication.
Reduced density by 91.5% in Eau Claire County at 3 weeks and 89.5% at 4 weeks postapplication.
Reduced density by 90.9% in Sauk County at 2 weeks and 97.6% at 3 weeks postapplication.
Limited treated homes with at least one nymphal tick posttreatment to a range of 4.2% (Eau Claire County, week 1) to 29.2% (Eau Claire County, week 3), compared to 50-81.5% of placebo homes.
Lowered the odds of detecting a nymphal tick in treated plots to 0.04 times that of placebo plots at week 1 and 0.09 times that of placebo plots at week 3, after adjusting for plot characteristics and study area.
Animal Model: Long-Evans (male, 63-67 days old, 331.1-361.7 g)
Dosage: 0.0938 mg/kg, 0.188 mg/kg, 0.375 mg/kg, 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg; additional pilot doses: 0.3 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg
Administration: p.o.; single dose
Result: Produced statistically significant decreases in locomotor activity counts relative to controls at doses ≥0.75 mg/kg.
Achieved an ED50 of 1.29 mg/kg for reducing locomotor activity.
Reached a benchmark dose (BMD) of 0.256 mg/kg for a 1 standard deviation decrease in activity.
Induced salivation at 13% incidence with 0.75 mg/kg, 17% incidence with 1 mg/kg, 69% incidence with 1.5 mg/kg, 92% incidence with 2 mg/kg, and 100% incidence with 3 mg/kg and 4 mg/kg.
Associated a 50% decrease in locomotor activity with a plasma concentration of 486.1 ng/mL and a brain concentration of 13.37 ng/g.
Showed a strong positive linear correlation between brain and plasma concentrations, with both tissue levels correlating significantly with decreases in locomotor activity counts.

化学信息

分子量 449.85
分子式 C23H19ClF3NO3
CAS No. 76703-62-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础